Breaking News
January 21, 2019 - FDA Advisory Committee Votes on Zynquista (sotagliflozin) as Treatment for Adults with Type 1 Diabetes
January 21, 2019 - The causes and complications of snoring
January 21, 2019 - Placenta adapts and compensates when pregnant mothers have poor diets or low oxygen
January 21, 2019 - New implant could restore the transmission of electrical signals in injured central nervous system
January 21, 2019 - Rapid-acting fentanyl test strips found to be effective at reducing overdose risk
January 21, 2019 - Coronary Artery Calcium May Help Predict CVD in South Asians
January 21, 2019 - The mystery of the super-ager
January 21, 2019 - Scientists develop smart microrobots that can change shape depending on their surroundings
January 21, 2019 - Keep Moving to Keep Brain Sharp in Old Age
January 21, 2019 - Despite progress, gay fathers and their children still structurally stigmatized
January 21, 2019 - Merck recognized with 2018 Life Science Industry Award for best use of social media
January 21, 2019 - Coeur Wallis equips the canton of Valais with 260 SCHILLER defibrillators
January 21, 2019 - Scientists propose quick and pain-free method for diagnosing kidney cancer
January 21, 2019 - Signs of memory loss could point to hearing issues
January 21, 2019 - HeartFlow Analysis shows highest diagnostic performance for detecting coronary artery disease
January 21, 2019 - How Much Caffeine is Too Much?
January 21, 2019 - Take a timeout before you force your child to apologize
January 21, 2019 - Scientists design two AI algorithms to improve early detection of cognitive impairment
January 21, 2019 - Novel therapy for children with chronic hormone deficiency provides lifeline for parents
January 21, 2019 - Bioethicists call for oversight of poorly regulated, consumer-grade neurotechnology products
January 21, 2019 - Study shows hereditary hemochromatosis behind many cancers and joint diseases
January 21, 2019 - Short bouts of stairclimbing throughout the day can improve cardiovascular health
January 20, 2019 - Liver Transplant Survival May Improve With Race Matching
January 20, 2019 - Study implicates hyperactive immune system in aging brain disorders
January 20, 2019 - Cancer Diagnosis May Quadruple Suicide Risk
January 20, 2019 - Parkinson’s disease experts devise a roadmap
January 20, 2019 - Research brings new hope to treating degenerative brain diseases
January 20, 2019 - Scientists pinpoint a set of molecules that wire the body weight center of the brain
January 20, 2019 - Researchers get close to developing elusive blood test for Alzheimer’s disease
January 20, 2019 - UCLA researchers demonstrate new technique to develop cancer-fighting T cells
January 20, 2019 - Researchers discover how cancer cells avoid genetic meltdown
January 20, 2019 - Exercise makes even the ‘still overweight’ healthier: study
January 20, 2019 - University of Utah to establish first-of-its-kind dark sky studies minor in the US
January 20, 2019 - School-based nutritional programs reduce student obesity
January 20, 2019 - Improved maternity care practices in the southern U.S. reduce racial inequities in breastfeeding
January 20, 2019 - New enzyme biomarker test indicates diseases and bacterial contamination
January 20, 2019 - Republican and Democratic governors have different visions to transform health care, say researchers
January 20, 2019 - Researchers discover that spin flips happen in only half a picosecond in the course of a chemical reaction
January 20, 2019 - Suicide Risk Up More Than Fourfold for Cancer Patients
January 20, 2019 - Doctors find 122 nails in Ethiopian’s stomach
January 20, 2019 - UV disinfection technology eliminates up to 97.7% of pathogens in operating rooms
January 20, 2019 - Researchers discover mechanism which drives leukemia cell growth
January 20, 2019 - AHA: Infection as a Baby Led to Heart Valve Surgery for Teen
January 20, 2019 - Injection improves vision in a form of childhood blindness
January 20, 2019 - Multiple sclerosis therapies delay progression of disability
January 20, 2019 - New study finds infrequent helmet use among bike share riders
January 20, 2019 - Clearing up information about corneal dystrophies
January 20, 2019 - Researchers describe new behavior in energy metabolism that refutes existing evidence
January 20, 2019 - New study takes first step toward treating endometriosis
January 20, 2019 - Researchers find how GREB1 gene promotes resistance to prostate cancer treatments
January 20, 2019 - Replacing Sitting Time With Activity Lowers Mortality Risk
January 20, 2019 - A simple, inexpensive intervention makes birth safer for moms and babies in parts of Africa
January 19, 2019 - New anti-inflammatory compound acts as ‘surge protector’ to reduce cancer growth
January 19, 2019 - Significant flaws found in recently released forensic software
January 19, 2019 - New Leash on Life? Staying Slim Keeps Pooches Happy, Healthy
January 19, 2019 - Men and women remember pain differently
January 19, 2019 - Rising air pollution linked with increased ER visits for breathing problems
January 19, 2019 - Study uses local data to model food consumption patterns among Seattle residents
January 19, 2019 - The brain’s cerebellum plays role in controlling reward and social behaviors, study shows
January 19, 2019 - Relationship between nurse work environment and patient safety
January 19, 2019 - Pioneering surgery restores movement to children paralyzed by acute flaccid myelitis
January 19, 2019 - Genetic variants linked with risk tolerance and risky behaviors
January 19, 2019 - New research provides better understanding of our early human ancestors
January 19, 2019 - First-ever tailored reporting guidance to improve patient care and outcomes
January 19, 2019 - 4.6 percent of Massachusetts residents have opioid use disorder
January 19, 2019 - New study suggests vital exhaustion as risk factor for dementia
January 19, 2019 - New antibiotic discovery heralds breakthrough in the fight against drug-resistant bacteria
January 19, 2019 - Ural Federal University scientists synthesize a group of multi-purpose fluorophores
January 19, 2019 - Researchers identify new therapeutic target in the fight against chronic liver diseases
January 19, 2019 - Preparation, characterization of Soyasapogenol B loaded onto functionalized MWCNTs
January 19, 2019 - FDA Approves Ontruzant (trastuzumab-dttb), a Biosimilar to Herceptin
January 19, 2019 - Tobacco use linked with higher use of opioids and sedatives
January 19, 2019 - Study delves deeper into developmental dyslexia
January 19, 2019 - Anti-vaccination movement one of the top health threats in 2019 says WHO
January 19, 2019 - Newly developed risk score more effective at identifying type 1 diabetes
January 19, 2019 - Highly effective protocol to prepare cannabis samples for THC/CBD analysis
January 19, 2019 - Prinston Pharmaceutical Inc. Issues Voluntary Nationwide Recall of Irbesartan and Irbesartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodiethylamine (NDEA) in the Products
January 19, 2019 - How does solid stress from brain tumors cause neuronal loss, neurologic dysfunction?
January 19, 2019 - $14.7 million partnership to supercharge vaccine development
January 19, 2019 - Ian Fotheringham receives Charles Tennant Memorial Lecture award
Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients

Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients

image_pdfDownload PDFimage_print

NEW YORK & INDIANAPOLIS–(BUSINESS WIRE October 23, 2018 )–Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today
announced complete results from a Phase 3 study evaluating the efficacy
and safety of subcutaneous administration of tanezumab, an
investigational humanized monoclonal antibody, in patients with
osteoarthritis (OA) pain treated for 16 weeks. The study met all three
co-primary efficacy endpoints, demonstrating that among patients with
moderate-to-severe OA pain of the knee or hip, both dosing regimens of
tanezumab were associated with a statistically significant improvement
in pain, physical function and patient’s global assessment of their OA,
compared to placebo. These data were presented during a late-breaking
oral session at the 2018 American College of Rheumatology/Association of
Rheumatology for Health Professionals (ACR/ARHP) Annual Meeting in
Chicago.

“The results demonstrated by tanezumab in this study are particularly
meaningful, given that patients had moderate-to-severe pain and were
unable to achieve adequate pain relief with other treatment options,
including opioids and NSAIDs,” said Ken Verburg, tanezumab development
team leader, Pfizer Global Product Development. “Our goal is to be able
to offer tanezumab as a potential non-opioid treatment option for these
patients suffering from osteoarthritis pain.”

More than 27 million Americans are living with OA, a progressive disease
that can cause ongoing debilitating pain. Treatments for OA pain are
limited, and many individuals are unable to find relief from or tolerate
currently available options. Tanezumab is part of an investigational
class of pain medications known as nerve growth factor (NGF) inhibitors,
and in addition to OA pain, is also being studied as a potential
treatment for chronic low back pain (CLBP) and cancer pain (due to bone
metastases). If approved, tanezumab would be a first-in-class,
non-opioid treatment for OA pain and CLBP.

“Pfizer and Lilly each have a long-standing heritage of scientific
innovation in developing novel pain treatments and a shared commitment
to the development of tanezumab,” said Christi Shaw, senior vice
president, Eli Lilly and Company and president, Lilly Bio-Medicines.
“These initial results from our Phase 3 program for tanezumab are
promising, and we’re eager to gain further insights as additional data
report out next year.”

The Phase 3 OA study evaluated changes from baseline to 16 weeks for
three co-primary efficacy endpoints of pain intensity and physical
function, assessed using the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) subscale and patient’s overall assessment
of their OA (PGA-OA). At 16 weeks of treatment, tanezumab was associated
with a significant reduction in pain compared to placebo; additional
efficacy findings are detailed in the table below.

Placebo

Tanezumab

2.5 mg

Tanezumab

2.5/5 mg

N = 232 N = 231 N = 233
WOMAC Pain: Change from Baseline (p-value) versus placebo -2.6 -3.2* -3.4**
Reduction from Baseline at Week 16
≥30% 54.7% 68.0%** 70.4%***
≥50% 37.9% 54.5%*** 57.1%***
≥70% 25.0% 34.6%* 36.5%**
≥90% 9.5% 14.7% 14.2%
WOMAC Physical Function: Change from Baseline (p-value)
versus placebo
-2.6 -3.2** -3.5***
PGA-OA: Change from Baseline (p-value) versus placebo -0.65 -0.87* -0.90**

*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 vs. placebo

In the study, nasopharyngitis (common cold), pain in extremity and
paresthesia (tingling or numbing) were the most common adverse events
(AEs ≥3%) and had a higher frequency in both tanezumab treatment groups
compared to placebo-treated patients. Tanezumab was generally well
tolerated, with 0.4 percent and 1.3 percent of patients in the tanezumab
2.5 mg and 2.5/5 mg arms, respectively, discontinuing treatment due to
AEs; 1.3 percent of patients in the placebo arm discontinued treatment
due to AEs.

There were no cases of osteonecrosis observed in the study. Rapidly
progressive osteoarthritis (RPOA) was observed with tanezumab-treated
patients at a frequency of 1.3 percent and was not observed in the
placebo arm. The incidence of RPOA type 1 (accelerated joint space
narrowing) in the tanezumab 2.5 mg and 2.5/5 mg arms was 1.3 and 0.4
percent, respectively, and the incidence of RPOA type 2 (damage or
deterioration of the joint) was 0.9 and 0 percent, respectively. In the
study, 3.5 percent and 6.9 percent of patients receiving tanezumab 2.5
mg and 2.5/5 mg, respectively, had total joint replacement surgery,
compared to 1.7 percent receiving placebo. The majority of surgeries (68
percent) took place after treatment was completed, during or shortly
after the 24-week safety follow-up period of the study. All surgeries in
this study took place among patients with more severe OA at screening
(Kellgren-Lawrence grade 3-4).

The Phase 3 global clinical development program evaluating the efficacy
and safety of tanezumab includes six studies in approximately 7,000
patients with OA pain, CLBP and cancer pain (due to bone metastases).
Additional readouts from the Phase 3 program are anticipated beginning
in the first half of 2019.

About the Study

The Phase 3 OA study (A4091056) was a 16-week randomized, double-blind,
placebo-controlled, multicenter, parallel-group trial evaluating the
efficacy and safety of subcutaneous administration of tanezumab compared
to placebo in patients with OA of the knee or hip. The trial included a
24-week safety follow-up period. In the study, patients were enrolled
with moderate-to-severe OA pain who had experienced inadequate pain
relief with other treatment options for OA pain or were unable to take
other pain medications. A total of 698 patients were randomized to three
treatment groups in a 1:1:1 ratio to receive two injections over the
16-week treatment period, once every eight weeks; 696 patients received
treatment. One group received two doses of placebo, the second group
received two doses of tanezumab 2.5 mg, and the third group received one
dose of tanezumab 2.5 mg followed by one dose of tanezumab 5 mg eight
weeks later.

Efficacy in the study was measured based on change from baseline to 16
weeks using the WOMAC Pain and Physical Function subscales (11-point
numerical rating scale, where higher scores indicate higher pain levels
or worse function) and PGA-OA scores (5-point numerical rating of the
patient’s condition, where 1 equals “very good” and 5 equals “very
poor”). The average baseline scores for this moderate-to-severe patient
population were as follows: the WOMAC Pain and Physical Function
subscales were approximately 7.1 to 7.4, and the PGA-OA scores were
approximately 3.4 to 3.5 across the treatment groups.

About Tanezumab

Tanezumab is an investigational humanized monoclonal antibody that works
by selectively targeting, binding to and inhibiting NGF. NGF levels
increase in the body as a result of injury, inflammation or in chronic
pain states. By inhibiting NGF, tanezumab may help to keep pain signals
produced by muscles, skin and organs from reaching the spinal cord and
brain. Tanezumab has a novel mechanism that acts in a different manner
than opioids and other analgesics, including nonsteroidal
anti-inflammatory drugs (NSAIDs), and in studies to date, tanezumab has
not demonstrated a risk of addiction, misuse or dependence.

In 2013, Pfizer and Lilly entered into a worldwide co-development and
co-commercialization agreement for the advancement of tanezumab. In June
2017, Pfizer and Lilly announced that the U.S. Food and Drug
Administration (FDA) granted Fast Track designation for tanezumab for
the treatment of OA pain and CLBP. Tanezumab is the first NGF inhibitor
to receive Fast Track designation, a process designed to facilitate the
development and expedite the review of new therapies that treat serious
conditions and fill unmet medical needs.

About Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies
to people that extend and significantly improve their lives. We strive
to set the standard for quality, safety and value in the discovery,
development and manufacture of health care products. Our global
portfolio includes medicines and vaccines as well as many of the world’s
best-known consumer health care products. Every day, Pfizer colleagues
work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases
of our time. Consistent with our responsibility as one of the world’s
premier innovative biopharmaceutical companies, we collaborate with
health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world. For
more than 150 years, we have worked to make a difference for all who
rely on us. We routinely post information that may be important to
investors on our website at www.pfizer.com.
In addition, to learn more, please visit us on www.pfizer.com and
follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and
like us on Facebook at Facebook.com/Pfizer.

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to
make life better for people around the world. We were founded more than
a century ago by a man committed to creating high-quality medicines that
meet real needs, and today we remain true to that mission in all our
work. Across the globe, Lilly employees work to discover and bring
life-changing medicines to those who need them, improve the
understanding and management of disease, and give back to communities
through philanthropy and volunteerism. To learn more about Lilly, please
visit us at www.lilly.com and http://newsroom.lilly.com/socialchannels.

PFIZER DISCLOSURE NOTICE: The information contained in this release
is as of October 23, 2018. Pfizer assumes no obligation to update
forward-looking statements contained in this release as the result of
new information or future events or developments.

This release contains forward-looking information about a product
candidate, tanezumab, including its potential benefits, that involves
substantial risks and uncertainties that could cause actual results to
differ materially from those expressed or implied by such statements.
Risks and uncertainties include, among other things, the uncertainties
inherent in research and development, including the ability to meet
anticipated clinical trial commencement and completion dates and
regulatory submission dates, as well as the possibility of unfavorable
clinical trial results, including unfavorable new clinical data and
additional analyses of existing clinical data; the risk that clinical
trial data are subject to differing interpretations, and, even when we
view data as sufficient to support the safety and/or effectiveness of a
product candidate, regulatory authorities may not share our views and
may require additional data or may deny approval altogether; whether
regulatory authorities will be satisfied with the design of and results
from our clinical studies; whether and when new drug applications may be
filed in any jurisdictions for tanezumab; whether and when any such
applications may be approved by regulatory authorities, which will
depend on the assessment by such regulatory authorities of the
benefit-risk profile suggested by the totality of the efficacy and
safety information submitted and, if approved, whether tanezumab will be
commercially successful; decisions by regulatory authorities regarding
labeling and other matters that could affect the availability or
commercial potential of tanezumab; and competitive developments.

A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended December
31, 2017 and in its subsequent reports on Form 10-Q, including in the
sections thereof captioned “Risk Factors” and “Forward-Looking
Information and Factors That May Affect Future Results”, as well as in
its subsequent reports on Form 8-K, all of which are filed with the U.S.
Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

LILLY DISCLOSURE NOTICE: This press release contains forward-looking
statements (as that term is defined in the Private Securities Litigation
Reform Act of 1995) about tanezumab as a potential treatment for
patients with osteoarthritis, chronic low back pain, and cancer pain,
and reflects Lilly’s current beliefs. However, as with any
pharmaceutical product, there are substantial risks and uncertainties in
the process of drug development and commercialization. Among other
things, there is no guarantee that future study results will be
consistent with study findings to date, or that tanezumab will be
approved by the U.S. FDA or other regulatory authorities on the
anticipated timeline or at all, or that tanezumab will be commercially
successful. For further discussion of these and other risks and
uncertainties, see Lilly’s most recent Form 10-K and Form 10-Q filings
with the United States Securities and Exchange Commission. Except as
required by law, Lilly undertakes no duty to update forward-looking
statements to reflect events after the date of this release.

Source: Pfizer Inc.

Posted: October 2018

Tagged with:

About author

Related Articles